



Alnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference

January 2, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2018-- [Alnylam Pharmaceuticals, Inc.](#) (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 8:00 am PT (11:00 am ET) at The Westin St. Francis in San Francisco. In addition, the company will webcast the Q&A breakout session immediately following its presentation at 8:30 am PT (11:30 am ET).

A live audio webcast of both the presentation and breakout session will be available on the Investors section of the company's website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 600 people in the U.S. and Europe and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at [@Alnylam](#) or on [LinkedIn](#).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180102005557/en/>

Source: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

(Investors and Media)

Christine Regan Lindenboom, 617-682-4340

or

(Investors)

Josh Brodsky, 617-551-8276